---
title: "Century Therapeutics 2Q 2026: Revenue $0 EPS $(0.17) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295662953.md"
description: "Century Therapeutics reported Q2 2026 results with $0 revenue and a net loss of $34.6M (EPS $(0.17)), compared to a $32.5M loss in the prior year. The company advanced IND-enabling studies for CNTY-813, targeting an IND filing in Q4 2026. Operational efficiencies were achieved through cost realignment, while cash reserves are projected to sustain operations through Q1 2029."
datetime: "2026-08-12T12:11:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295662953.md)
  - [en](https://longbridge.com/en/news/295662953.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295662953.md)
generator: "portal-rs"
---

# Century Therapeutics 2Q 2026: Revenue $0 EPS $(0.17) — 10-Q Summary

Century Therapeutics, Inc. reported results for the quarter ended 2Q 2026, posting revenue of $0 and a net loss of $34.6M, or diluted EPS of $(0.17), compared with a net loss of $32.5M and diluted EPS of $(0.38) in the year‑ago quarter.

**Financial Highlights**

-   Revenue was $0 for Q2 2026, versus $0 for Q2 2025 (BMS collaboration revenue of $109.2M was recognized in 1H 2025, not in Q2 2025).
-   Net income was $(34.6) M for Q2 2026, compared with $(32.5) M in Q2 2025 (loss increased (6.3%) year over year).
-   Diluted EPS was $(0.17) for Q2 2026, versus $(0.38) for Q2 2025.

**Business Highlights**

-   Pipeline progress: IND‑enabling studies advancing for lead CNTY‑813 islet therapy; IND planned for Q4 2026 with initial clinical data anticipated in H2 2027.
-   Platform & differentiation: Continued development of Allo‑Evasion™ v5.0 and iPSC‑derived islet, CAR‑iT (CNTY‑308) and iNK programs focused on scalable, off‑the‑shelf manufacturing.
-   Operational milestones: Established a Phase 1 clinical manufacturing process for CNTY‑813 across three independent batches and presented supporting preclinical efficacy and immune‑evasion data.
-   Cost realignment: R&D and G&A headcount and facility allocations reduced through portfolio prioritization to lower near‑term operating spend and refocus programs.
-   Liquidity: Cash and investments are expected to support operations into Q1 2029, enabling ongoing IND‑enabling work and manufacturing scale‑up.

Original SEC Filing: Century Therapeutics, Inc. \[ IPSC \] - 10-Q - Aug. 12, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [IPSC.US](https://longbridge.com/en/quote/IPSC.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Century Therapeutics Reports Q2 Results, Pipeline Advancements](https://longbridge.com/en/news/295668584.md)
- [Seven Fleet Capital Management LP Takes Position in Century Therapeutics, Inc. $IPSC](https://longbridge.com/en/news/294604045.md)
- [Century Therapeutics (IPSC) Gets a Buy from Mizuho Securities](https://longbridge.com/en/news/296141006.md)
- [HC Wainwright Issues Pessimistic Forecast for IPSC Earnings](https://longbridge.com/en/news/296058102.md)
- [Century Therapeutics (IPSC) Swings To US$0.51 EPS Profit Challenging Persistent Loss Narratives](https://longbridge.com/en/news/278972725.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**